265 related articles for article (PubMed ID: 17489984)
1. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Réjiba S; Wack S; Aprahamian M; Hajri A
Cancer Sci; 2007 Jul; 98(7):1128-36. PubMed ID: 17489984
[TBL] [Abstract][Full Text] [Related]
2. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells.
Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H
Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439
[TBL] [Abstract][Full Text] [Related]
3. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
5. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
6. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
7. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo.
Zhu H; Liang ZY; Ren XY; Liu TH
Cancer Biol Ther; 2006 Dec; 5(12):1693-8. PubMed ID: 17106254
[TBL] [Abstract][Full Text] [Related]
8. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
9. Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells.
Niu W; Liu X; Zhang Z; Xu K; Chen R; Liu E; Wang J; Peng C; Niu J
Anticancer Res; 2010 Jan; 30(1):135-42. PubMed ID: 20150628
[TBL] [Abstract][Full Text] [Related]
10. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
11. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207.
You L; Wang H; Yang G; Zhao F; Zhang J; Liu Z; Zhang T; Liang Z; Liu C; Zhao Y
Mol Oncol; 2018 Dec; 12(12):2147-2164. PubMed ID: 30341811
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
14. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.
Liu WS; Yan HJ; Qin RY; Tian R; Wang M; Jiang JX; Shen M; Shi CJ
Dig Dis Sci; 2009 Jan; 54(1):89-96. PubMed ID: 18594980
[TBL] [Abstract][Full Text] [Related]
15. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Matsuda Y; Ishiwata T; Yoshimura H; Yamashita S; Ushijima T; Arai T
Pancreas; 2016 Jan; 45(1):93-100. PubMed ID: 26335012
[TBL] [Abstract][Full Text] [Related]
16. siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway.
Liu D; Zhang Y; Dang C; Ma Q; Lee W; Chen W
Oncol Rep; 2007 Sep; 18(3):673-7. PubMed ID: 17671718
[TBL] [Abstract][Full Text] [Related]
17. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
18. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
19. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
20. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
